がん領域のバイオシミラー市場：用途別、エンドユーザー別-2025-2030年の世界予測

がん領域のバイオシミラー市場は、2023年に46億5,000万米ドルと評価され、2024年には54億8,000万米ドルに達すると予測され、CAGR 18.11％で成長し、2030年には149億1,000万米ドルに達すると予測されています。

がん領域のバイオシミラーは、すでに承認されている参照生物製剤と類似性の高い生物学的製剤であり、より安価な選択肢を提供することでがん治療において重要な役割を果たしています。これらのバイオシミラー医薬品は、安全性、純度、有効性において基準品に匹敵するよう開発されており、ヘルスケアシステムと患者に大幅なコスト削減を提供しています。がん領域のバイオシミラーの必要性は、世界のがん罹患率の増加と生物学的製剤による治療に伴う持続不可能なコストから生まれています。がん領域のバイオシミラーは、モノクローナル抗体や補助療法を含む幅広いがん治療への応用が可能であり、主なエンドユーザーは病院、診療所、がん治療センターです。市場成長の原動力は、ブロックバスター生物製剤の特許切れ、ヘルスケア支出削減へのプレッシャーの高まり、バイオシミラー製造を合理化するバイオテクノロジーの進歩です。潜在的な治療機会は、費用対効果の高いがん治療を求める新興国の未開拓市場や、先発生物製剤の継続的な特許切れなどにあります。企業は、強固な研究開発と戦略的パートナーシップに投資し、競争力のある価格を確保し、薬事規制の道を効果的に進むことで、これらを活用することができます。しかし、市場の成長は、厳しい規制要件、高い開発コスト、医師や患者の懐疑心、バイオシミラー医薬品の互換性や代替性に関する問題などの課題に直面しています。技術革新と研究の最良の分野としては、歩留まり向上とコスト削減のための製造プロセスの改善、患者のコンプライアンス向上のためのデリバリーシステムの強化、競合情勢の中で差別化を図るための差別化戦略の開発などが挙げられます。市場の特徴は、高い競争と急速な技術進歩であり、有効性と安全性を実証するためのエビデンスに基づく結果が重視されます。企業は、技術革新を戦略的に活用し、利害関係者教育に積極的に取り組み、サプライチェーンのダイナミクスを最適化することで、成長を維持し、市場において足跡を広げていく必要があります。

市場力学：急速に進化するがん領域のバイオシミラー市場の主要市場インサイトを公開

がん領域のバイオシミラー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 規制当局による製品化の迅速な承認
  • 各種がんや白血病の罹患率の上昇
  • 臨床医薬品開発における最近の技術革新
• 市場抑制要因
  • 調査にかかるコストの高さ
• 市場機会
  • 新しく革新的な治療法のイントロダクション
  • 戦略的提携と能力拡大のための投資
• 市場の課題
  • 限られた臨床安全性と有効性データ

ポーターの5つの力がん領域のバイオシミラー市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん領域のバイオシミラー市場における外部からの影響の把握

外部マクロ環境要因は、がん領域のバイオシミラー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん領域のバイオシミラー市場における競合情勢の把握

がん領域のバイオシミラー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん領域のバイオシミラー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん領域のバイオシミラー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん領域のバイオシミラー市場における成功への道筋を描く

がん領域のバイオシミラー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 規制当局による製品の商業化の迅速な承認
    • さまざまな種類のがんや白血病の発生率の上昇
    • 臨床医薬品開発における最近のイノベーション
  • 抑制要因
    • 調査にかかる高額な費用
  • 機会
    • 新しい革新的な治療法のイントロダクション
    • 戦略的提携と生産能力拡大のための投資
  • 課題
    • 臨床安全性と有効性に関するデータは限られている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん領域のバイオシミラー市場：用途別

• がん治療薬
• 支持療法薬

第7章 がん領域のバイオシミラー市場：エンドユーザー別

• 病院
• 小売薬局

第8章 南北アメリカのがん領域のバイオシミラー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のがん領域のバイオシミラー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのがん領域のバイオシミラー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Allergan plc
• Amneal Pharmaceuticals LLC.
• Apotex Inc.
• Aurobindo Pharma Limited
• Bristol-Myers Squibb Company
• Cipla Inc.
• Eli Lilly and Company
• Endo International plc
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• JSC BIOCAD
• Lupin Limited
• Mylan N.V.
• Novartis AG

LIST OF FIGURES

• FIGURE 1. ONCOLOGY BIOSIMILARS MARKET RESEARCH PROCESS
• FIGURE 2. ONCOLOGY BIOSIMILARS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLOGY BIOSIMILARS MARKET DYNAMICS
• TABLE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY CANCER TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY SUPPORTIVE CARE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. POLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. QATAR ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 100. ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023

The Oncology Biosimilars Market was valued at USD 4.65 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 18.11%, to USD 14.91 billion by 2030.

Oncology biosimilars are biologic medical products highly similar to already approved reference biologics, playing a crucial role in cancer treatment by providing more affordable options. These biosimilars are developed to match their reference counterparts in terms of safety, purity, and efficacy, offering significant cost savings for healthcare systems and patients. The necessity for oncology biosimilars emerges from the growing global incidence of cancer and the unsustainable costs associated with biologic treatments. They find application across a wide range of oncological therapies including monoclonal antibodies and adjunctive therapies, with primary end-users being hospitals, clinics, and cancer treatment centers. Market growth is driven by patent expirations of blockbuster biologics, increasing pressure to reduce healthcare expenditures, and advancements in biotechnology that streamline biosimilar production. Potential opportunities lie in untapped markets in emerging economies, which are seeking cost-effective cancer treatments, and the continuous patent expiration of original biologics. Companies can capitalize on these by investing in robust R&D and strategic partnerships, ensuring competitive pricing, and navigating regulatory pathways effectively. However, market growth faces challenges such as stringent regulatory requirements, high development costs, physician/patient skepticism, and issues related to biosimilar interchangeability and substitution. The best areas for innovation and research include improving the manufacturing processes to increase yield and reduce cost, enhancing delivery systems for better patient compliance, and developing differentiation strategies to distinguish in the competitive landscape. The market is characterized by high competition and rapid technological advancements, with a strong focus on evidence-based outcomes to demonstrate efficacy and safety. Companies must strategically leverage technological innovations, engage in active stakeholder education, and optimize supply chain dynamics to sustain growth and broaden their footprint in the oncology biosimilars market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Biosimilars Market

The Oncology Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rapid approval by regulatory authorities for commercialization of products
  • Rising incidence of various types of cancers and leukemia
  • Recent innovation in clinical drug development
• Market Restraints
  • High costs involved in the research
• Market Opportunities
  • Introduction of new and innovative treatment options
  • Strategic alliances and investment for capacity expansion
• Market Challenges
  • Limited clinical safety and efficacy data

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Biosimilars Market

A detailed market share analysis in the Oncology Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Biosimilars Market

A strategic analysis of the Oncology Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Allergan plc, Amneal Pharmaceuticals LLC., Apotex Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Endo International plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, JSC BIOCAD, Lupin Limited, Mylan N.V., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Oncology Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Application, market is studied across Cancer Treatment Drugs and Supportive Care Drugs.
• Based on End-User, market is studied across Hospitals and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rapid approval by regulatory authorities for commercialization of products
    • 5.1.1.2. Rising incidence of various types of cancers and leukemia
    • 5.1.1.3. Recent innovation in clinical drug development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs involved in the research
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new and innovative treatment options
    • 5.1.3.2. Strategic alliances and investment for capacity expansion
  • 5.1.4. Challenges
    • 5.1.4.1. Limited clinical safety and efficacy data
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Biosimilars Market, by Application

• 6.1. Introduction
• 6.2. Cancer Treatment Drugs
• 6.3. Supportive Care Drugs

7. Oncology Biosimilars Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Retail Pharmacies

8. Americas Oncology Biosimilars Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Oncology Biosimilars Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Oncology Biosimilars Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Allergan plc
• 2. Amneal Pharmaceuticals LLC.
• 3. Apotex Inc.
• 4. Aurobindo Pharma Limited
• 5. Bristol-Myers Squibb Company
• 6. Cipla Inc.
• 7. Eli Lilly and Company
• 8. Endo International plc
• 9. F. Hoffmann-La Roche Ltd.
• 10. GlaxoSmithKline plc
• 11. Glenmark Pharmaceuticals Limited
• 12. JSC BIOCAD
• 13. Lupin Limited
• 14. Mylan N.V.
• 15. Novartis AG